



May 16, 2013

## **ImmunoCellular Therapeutics Announces Issuance of Key Patent Covering ICT-107 Cancer Vaccine Target**

LOS ANGELES--(BUSINESS WIRE)-- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) announced that the US Patent and Trademark Office (USPTO) has issued a patent covering methods of use of interleukin 13-receptor alpha 2 protein (IL-13R $\alpha$ 2) in cancer immunotherapy. IL-13 is an immune regulatory cytokine and IL-13R $\alpha$ 2 is highly and specifically expressed in glioblastoma, ovarian and other solid tumors, but not in normal tissue. IL-13R $\alpha$ 2 is an important target of ImmunoCellular's lead product candidate, ICT-107, a dendritic cell vaccine directed against glioblastoma antigens and cancer stem cells, as well as ICT-140, a dendritic cell vaccine to treat ovarian cancer.

"We believe that this issued patent will complement and extend the broad intellectual property protection we have established for two of our company's key assets, ICT-107 and ICT-140, and represents a valuable addition to our patent estate," said Andrew Gengos, ImmunoCellular Chief Executive Officer. "IL-13R $\alpha$ 2 is a tumor-associated antigen present in the majority of brain cancers, and we believe that using an immunotherapeutic vaccine that targets this and other specific antigens as well as cancer stem cells to stimulate an immune response represents a promising anticancer approach."

The IL-13R $\alpha$ 2 patent was issued to The Penn State Research Foundation, the technology transfer agent for The Pennsylvania State University, and is licensed to Targepeutics, Inc. ImmunoCellular is a sub-licensee of the patent.

### About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular is conducting a phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. ImmunoCellular's pipeline also includes ICT-121, a dendritic cell vaccine targeting CD133, and ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells. To learn more about ImmunoCellular, please visit [www.imuc.com](http://www.imuc.com).

### Forward-Looking Statements for ImmunoCellular Therapeutics

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including the risk that ICT-107 can be further successfully developed or commercialized. Additional risks and uncertainties are described in IMUC's most recently filed quarterly report on Form 10-Q and annual report on Form 10-K. Except as permitted by law, IMUC undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

ImmunoCellular Therapeutics, Ltd.  
Investor Relations  
Jane Green  
415-348-0010 direct  
415-652-4819 mobile  
[jane@jmgcomm.com](mailto:jane@jmgcomm.com)

Source: ImmunoCellular Therapeutics, Ltd.

News Provided by Acquire Media